Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
0–16
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Anaemia attributed to Chronic Kidney Disease (CKD)
Sixteen years of age or under
Documented CKD as demonstrated by estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m² (Schwartz equation) for ≥3 months if not on dialysis, or: Receiving dialysis
Treatment with darbepoetin alfa
Documented informed consent by a parent or authorised individual, if required, and assent by the patient if appropriate
You may not be if
Active malignancy or current chemotherapy or radiation therapy
Investigator unlikely to be able to obtain adequate follow-up information, or participant will not be available for follow-up assessment
Currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study; subject receiving other investigational agents
Clareo Health | European Union Registry in Paediatric Chronic Kidney Disease Patients Looking at Safety and Usage Patterns of Darbepoetin Alfa
